Bone Therapeutics's JTA-004 Fails to Meet its All Endpoints in P-III Study for Knee Osteoarthritis
Shots:
- The P-III study involves assessing JTA-004 (enhanced viscosupplement) vs PBO and the active comparator to reduce pain measured by the WOMAC pain subscale in patients with osteoarthritic pain in the knee
- The study showed that all treatment arms have similar efficacy- no significant difference in knee pain reduction b/w JTA-004- PBO- and active comparator @3mos. after treatment. JTA-004 have a favorable safety profile like PBO and comparator
- The company is focusing on the development of its core assets- the allogeneic cell therapy platform- including ALLOB- which is currently being evaluated in a P-IIb study in 178 patients with fresh tibial fractures at risk of delayed or non-union
| Ref: Globe Newswire | Image: Ortho Spine News
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com